INTERVIEW
Sustainability is a growing focus in biopharma. What steps is PharmaNXT taking to integrate ecofriendly practices in its manufacturing processes, especially for Single-Use products?
PharmNXT Biotech’ s Single-Use solutions support sustainability goals by reducing water wastage, chemical use, and resource consumption. Our products are designed to minimize waste, optimize clean-room space, and enhance operational efficiency. For example, the NXTbin container’ s cylindrical design maximizes storage capacity and workflow efficiency, while its 100 % drainability prevents product loss. Similarly, all our single-use consumables eliminate the need for energy-intensive cleaning and sterilization, further reducing water and chemical consumption. Additionally, localized production lowers transit times and reduces inventory wastage for customers through just-in-time logistics. PharmNXT Biotech is driving ecoconscious, high-efficiency bioprocessing solutions that align with global sustainability standards by integrating waste reduction, process efficiency, and sustainable material use.
How has been the company ' s financial performance in FY25 and your revenue target for FY 26?
PharmNXT Biotech has demonstrated strong financial growth in FY25, driven by expanding global partnerships, increased demand for single-use solutions, and enhanced production capacity.
As we look ahead to FY26, we are targeting multiple revenue growth, supported by strategic investments in capacity expansion, product innovation, and new market penetration.
What are your key goals in FY26? Any plans to expand your global footprint?
In FY26, our primary objectives include scaling our manufacturing capabilities, strengthening coinnovation initiatives, and expanding our product portfolio to address nextgeneration bioprocessing needs. With a strong foothold in 12 countries, including ASEAN, the U. S., and Europe, along with offices in Singapore and South Korea, we plan to deepen our global presence by forging new partnerships in key biopharma markets.
Additionally, we are committed to enhancing automation and developing high-performance solutions tailored for biosimilars, mRNA, and cell and gene therapy production.
36
BioVoiceNews | April 2025